Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At BioIntel, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.